EPS Diluted (Quarterly) Chart

View EPS Diluted (Quarterly) for CADL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EPS Diluted (Quarterly) Chart
Start Trial

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 -0.5248
March 31, 2026 -0.1421
December 31, 2025 -0.5373
September 30, 2025 -0.2053
June 30, 2025 -0.0931
March 31, 2025 0.1347
December 31, 2024 -0.3957
September 30, 2024 -0.3326
June 30, 2024 -0.7442
March 31, 2024 -0.2816
December 31, 2023 -0.3828
September 30, 2023 -0.2917
June 30, 2023 -0.3324
Date Value
March 31, 2023 -0.3041
December 31, 2022 -0.1759
September 30, 2022 -0.3007
June 30, 2022 -0.144
March 31, 2022 -0.0305
December 31, 2021 0.0461
September 30, 2021 -0.5633
June 30, 2021 -0.5953
March 31, 2021 -0.1536
December 31, 2020 -0.3595
September 30, 2020 -0.0876
June 30, 2020 -0.1002
March 31, 2020 -0.0608

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 0.1822
Alnylam Pharmaceuticals, Inc. 1.207
Anika Therapeutics, Inc. 0.2412
Savara, Inc. -0.1587
Vericel Corp. 0.0422

EPS Diluted (Quarterly) Related Metrics